A drug-discovery company priced a stock sale expected to bring in about $200 million before costs.

Recursion Pharmaceuticals (RXRX) priced a stock sale of 61.54 million shares at $3.25 per share, expected to raise about $200 million before costs. The offering includes participation from leading healthcare investors and is managed by Leerink Partners, Goldman Sachs, Morgan Stanley, and Evercore Group.

Original reporting
Published Oct 15, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 12:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$RXRX
Bearish
high confidence
Mentioned
$RXRX
Relevance
9/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$RXRXBearishHigh
01

Why it matters

The capital raise strengthens the balance sheet for ongoing trials but introduces dilution risk, likely prompting a near‑term price dip.

02

Market read

Primary disclosure of a sizable secondary offering; traders can act on expected short‑term price pressure.

03

What to watch

Potential strategic investors like ARK may provide supportive capital, mitigating dilution concerns.

Relevance 9/10Novelty 9/10Timing: immediate today

Background

Recursion is a clinical‑stage AI‑driven drug discovery company that has been expanding its pipeline across multiple therapeutic areas.

Company-level read

Ticker impact

$RXRXBearishHigh confidence
Context

Recursion announced pricing of a 61.5M share underwritten offering expected to raise about $200M, a fresh primary capital raise.

Expected impact

downward pressure as investors price in dilution from the $200M raise

Evidence & confidence

New primary financing of this size is material and the market typically reacts with a price dip.

Market effects

Adds to the pipeline of financing activity in the biotech AI‑drug discovery sector, may prompt peers to consider similar raises.

US biotech market sees fresh capital inflow, modest impact on broader market.

Limited to biotech investors; no broad macro effect.

Counterpoint

If the raise funds transformative AI platforms, the long‑term upside could outweigh short‑term dilution.

Key entities

  • Recursion Pharmaceuticals, Inc.

    AI‑enabled drug discovery firm issuing new shares.

  • Leerink Partners, Goldman Sachs, Morgan Stanley, Evercore

    Joint book‑running managers for the offering.

Related articles

$RXRXMed

Recursion Aligns With FDA On Phase 3 Trial Design For FAP Drug REC-4881; Stock Up

Recursion Pharmaceuticals (RXRX) aligned with the FDA on the Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial, expected to start in late 2027, will assess composite event-free survival as the primary endpoint. REC-4881 has shown a 47% median reduction in total polyp burden in Phase 1b/2 trials. RXRX shares were up 4.41% in premarket trading.

$RXRXMedAI 8/10

Recursion (RXRX) Q3 2026 Earnings Call Transcript

Recursion (RXRX) reported Q3 2026 earnings, highlighting clinical data for REC-4881 and REC-1245. REC-4881 showed significant reductions in polyp burden and safety. REC-1245 demonstrated early activity in solid tumors. The company secured $535M in partner cash inflows and extended cash runway to 2029. Operating expenses for 2026 were lowered to $375M, with 2027 expected under $360M. Sanofi and Roche collaborations advanced, with milestones and royalties. Fred Hassan was appointed board chair.

$RXRXMedAI 8/10

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call

Recursion Pharmaceuticals (RXRX) reported Q3 updates, including 55% and 50% median reductions in upper and lower GI polyp burdens, respectively. REC-1245 showed partial responses in advanced solid tumors. Sanofi exercised an option, triggering a $10M payment. RXRX raised $200M in financing, extending cash runway into 2029. The company expects to start a registrational study in 2H 2027.

$RXRXHighAI 8/10

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

Recursion Pharmaceuticals reported a narrower-than-expected Q3 2026 loss of 22 cents per share, with revenues of $18.55 million, up 258.5% YoY, driven by a $10 million Sanofi milestone payment. Operating expenses declined, and the company advanced its pipeline, including REC-4881 and REC-1245. RXRX shares are down 6.4% YTD.